LRB-1616/P2
MED:emw
2021 - 2022 LEGISLATURE
DOA:......Mott, BB0516 - Require training for pharmacists who dispense naloxone
For 2021-2023 Budget -- Not Ready For Introduction
An Act ...; relating to: the budget.
Analysis by the Legislative Reference Bureau
SAFETY AND PROFESSIONAL SERVICES
Dispensing of naloxone by pharmacists; training
This bill requires the Pharmacy Examining Board to promulgate rules requiring all pharmacists to receive training on delivering or dispensing an opioid antagonist. Opioid antagonists are prescription drugs, such as the drug naloxone, some of which can, when administered to a person undergoing an overdose on drugs such as heroin or prescription narcotics, have the effect of countering the effects of the overdose.
For further information see the state fiscal estimate, which will be printed as an appendix to this bill.
The people of the state of Wisconsin, represented in senate and assembly, do enact as follows:
Section
1. 450.02 (2c) of the statutes is created to read:
450.02 (2c) The board shall promulgate rules to require all pharmacists to receive training on delivering or dispensing an opioid antagonist.
Section
2. 450.085 (1) of the statutes is amended to read:
450.085 (1) An applicant for renewal of a license under s. 450.08 (2) (a) shall submit proof that he or she has completed, within the 2-year period immediately preceding the date of his or her application, 30 hours of continuing education in courses conducted by a provider that is approved by the Accreditation Council for Pharmacy Education or in courses approved by the board. The board may approve training prescribed under s. 450.02 (2c) as continuing education for purposes of this subsection. Courses specified in s. 450.035 (1r) and (2) are courses in continuing education for purposes of this subsection. This subsection does not apply to an applicant for renewal of a license that expires on the first renewal date after the date on which the board initially granted the license.
Section 9138.
Nonstatutory provisions; Safety and Professional Services.
(1) Pharmacists; opioid antagonists. Using the procedure under s. 227.24, the pharmacy examining board may promulgate rules required under s. 450.02 (2c). Notwithstanding s. 227.24 (1) (c) and (2), emergency rules promulgated under this subsection remain in effect until May 1, 2023, or the date on which permanent rules take effect, whichever is sooner. Notwithstanding s. 227.24 (1) (a) and (3), the board is not required to provide evidence that promulgating a rule under this subsection as an emergency rule is necessary for the preservation of the public peace, health, safety, or welfare and is not required to provide a finding of emergency for a rule promulgated under this subsection.
(End)
